Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by priceless2on May 17, 2012 1:38pm

276 Views

Post# 19921547

No insider sales at all

What give me great comfort on holding all my shares in RVX and buying new shares is that the 2 major stock holders NGN biotech and Eastern capital have not shed one single share of RVX. To me that bodes alot of confidence in the science and the eventual sale or partnerships in the future. Secondly, I have not seen any of the managment sell one single share as well.

It is my opinion that the next 12 months will definately be very interesting in the share price

Stay classy San Diego

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects